2021 saw PharmaBoardroom’s network of executives and experts weighing in on some of the most pressing issues facing our industry today. See below…

The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new…

Long established as a premier early launch country for innovative medicines within Europe, the Danish market access system has become more complicated…

Spanish native Enrique Álvarez gives an overview of Denmark’s importance to Merck as a key European early launch market, a crucial clinical trial…

In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General…

As part of Saudi Arabia’s ambitious ‘Vision 2030’ economic transformation plan, the country has centralised the public procurement of…

Merck Switzerland’s Christiane von der Eltz highlights the German firm’s recent big investments in Switzerland and how it forms a key part of…

Historically dependent on oil, Saudi Arabia, like most countries in the Arabian Peninsula, is now investing a large chunk of the sizeable resources…

The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role…

Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland outlines how AI has already begun to transform pharmaceutical…

Haitham Habashi, general manager for Merck Saudi Arabia, outlines his affiliate’s approach to the big reforms shaping the country’s healthcare…

A roundup of some of the most important recent news from German pharma, including state honours for the founders of BioNTech, the latest on vaccines…